FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.667,86 +442,20 (+1,16%) Nasdaq
16.156,23 +315,27 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,39 -0,56 (-0,71%) Bitcoin EUR
57.507,72 +2.707,59 (+4,94%)
Arch Therapeutics, Inc. (ARTH)
| Chiusura precedente | 1,0100 |
| Aperto | 1,0100 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 1,0100 - 1,0600 |
| Intervallo di 52 settimane | 0,3900 - 18,0000 |
| Volume | |
| Media Volume | 3.345 |
| Capitalizzazione | 5,027M |
| Beta (5 anni mensile) | 3,56 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,4000 |
| Prossima data utili | 20 mag 2024 - 24 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireArch Therapeutics Provides AC5® Commercialization Update
Orders and Paid Claims Increasing Since Rollout of Reimbursement CodeFRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure Codi
- GlobeNewswire
Arch Therapeutics Completes Financing as Bridge to Uplisting
Common Stock Listing on National Exchange is Next Planned Significant MilestoneFRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement with institutional and accredited individual investors (collectively, the “Investors”) as a Bridge Offering preceding a planned national exchange listing of the
